top of page

Original on Transparent.png

Anti-obesity medications aggregator

Phase 2 data in obese, non-diabetic patients

For phase 1 click here

References (each reference is linked to the publication/ press release):

1. Danuglipron data from: Saxena AR et al. Diabetes Obes Metab. 2023 Oct;25(10):2805-2814;

3. Cagrilintide and liraglutide data from: David CW Lau et al. Lancet. 2021 Dec 11;398(10317):2160-2172;

2. GSBR 1290 data from: STRUCTURE Therapeutics - Corporate presentation;

4. Pemvidutide data from ALTIMMUNE – Corporate presentation;

5. VK2735 data from VIKING Therapeutics - Corporate presentation;

6. Survodutide data from: le Roux CW et al. Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173;

7. Retatrutide data from: Jastreboff AM et al. N Engl J Med. 2023 Aug 10;389(6):514-526;

bottom of page